Lipid and apolipoprotein predictors of atherosclerosis in youth. Apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 753-761

  Rainwater, David L ^a   McMahan, C Alex ^b   Malcom, Gray T ^c   Scheer, W Douglas ^c   Roheim, Paul S ^c   McGill Jr , Henry C ^a,b   Strong, Jack P ^c  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

apo(a); apoAl; apoB; Atherosclerosis; Lipoproteins; Lp(a); PDAY

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A;

ABDOMINAL AORTA; ADOLESCENT; ADULT; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THORACIC AORTA;

EID: 0032975498     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.753     Document Type: Article

References (66)

1. Gofman JW, Glazier F, Tamplin A, Strisower B, De Lalla O. Lipoproteins, coronary heart disease, and atherosclerosis. Physiol Rev. 1954;34:589-607.
2. Kunkel HG, Slater RJ. Lipoprotein patterns of serum obtained by zone electrophoresis. J Clin Invest. 1952;31:677-684.
3. Cohn EJ, Gurd FRN, Surgenor DM, Barnes BA, Brown RK, Derouaux G, Gillespie JM, Kahnt FW, Lever WF, Liu CH, Mittleman D, Mouton RF, Schmid K, Uroma E. A system for the separation of the components of human blood: quantitative procedures for the separation of the protein components of human plasma. J Am Chem Soc. 1950;72:465-474.
4. Heiskell CL, Fisk RT, Florsheim WH, Tachi A, Goodman JR, Carpenter CM. A simple method for quantitation of serum beta-lipoproteins by means of the immunocrit. Am J Clin Pathol. 1961;35:222-226.
5. Kahan J, Sundblad L. Immunochemical determination of β-lipoproteins. Scand J Clin Lab Invest. 1969;24:61-68.
6. Alaupovic P. Apolipoproteins and lipoproteins. Atherosclerosis. 1971;13: 141-146.
7. Sniderman AD, Silberberg J. Is it time to measure apolipoprotein B? Arteriosclerosis. 1990;10:665-667.
8. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 1990;10:668-671.
9. PDAY Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018-3024.
10. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, PDAY Research Group. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15: 431-440.
11. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol. 1997;17:95-106.
12. Guzmán MA, McMahan CA, McGill HC Jr, Strong JP, Tejada C, Restrepo C, Eggen DA, Robertson WB, Solberg LA. Selected methodologic aspects of the International Atherosclerosis Project. Lab Invest. 1968;18:479-497.
13. PDAY Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY study. Arterioscler Thromb. 1993;13:1291-1298.
14. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
15. Burstein M, Samaille J. Sur un dosage rapide du cholesterol lie aux α- et aux β-lipoproteines du serum. Clin Chim Acta. 1960;5:609.
16. Glanville JN. Post-mortem serum cholesterol levels. BMJ. 1960;2: 1852-1853.
17. Enticknap JB. Lipids in cadaver sera after fatal heart attacks. J Clin Pathol. 1961;14:496-499.
18. Hornick CA, Baker HN, Newman WP, Roheim PS, Strong JP. Lipoproteins and apolipoproteins in postmortem serum. Mod Pathol. 1988;1:480-484.
19. Doetsch K, Roheim PS, Thompson JJ. Human lipoprotein(a) quantified by 'capture' ELISA. Ann Clin Lab Sci. 1991;21:216-224.
20. Doetsch KM, Roheim PS, Thompson JJ. Optimization and characterization of capture ELISA methodology for Lp(a) lipoprotein quantification. Ann Clin Biochem. 1992;29:275-282.
21. Duvic CR, Smith G, Sledge WE, Lee LT, Murray MD, Roheim PS, Gallaher WR, Thompson JJ. Identification of a mouse monoclonal antibody, LHLP-1, specific for human Lp(a). J Lipid Res. 1985;26: 540-548.
22. Rainwater DL, Manis GS, VandeBerg JL. Hereditary and dietary effects on apolipoprotein[a] isoforms and Lp[a] in baboons. J Lipid Res. 1989; 30:549-558.
23. Rainwater DL. Genetic basis for multimodal relationship between apolipoprotein(a) size and lipoprotein(a) concentration in Mexican-Americans. Atherosclerosis. 1995;115:165-171.
24. Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol. 1998;18:1335-1341.
25. Taddei-Peters WC, Butman BT, Jones GR, Venetta TM, Macomber PF, Ransom JH. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin Chem. 1993;39:1382-1389.
26. Draper NR, Smith H. Applied Regression Analysis. New York: John Wiley & Sons; 1966:58-134.
27. Carroll RJ, Ruppert D. Transformation and Weighting in Regression. New York: Chapman&Hall; 1988.
28. McGill HC Jr, Strong JP, Tracy RE, McMahan CA, Oalmann MC, PDAY Research Group. Relation of a postmortem renal index of hypertension to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15: 2222-2228.
29. McGill HC Jr, McMahan CA, Tracy RE, Oalmann MC, Cornhill JF, Herderick EE, Strong JP, PDAY Research Group. Relation of a postmortem renal index of hypertension to atherosclerosis and coronary artery size in young men and women. Arterioscler Thromb Vasc Biol. 1998;18: 1108-1118.
30. Donahue RP, Jacobs DR Jr, Sidney S, Wagenknecht LE, Albers JJ, Hulley SB. Distribution of lipoproteins and apolipoproteins in young adults: the CARDIA study. Arteriosclerosis. 1989;9:656-664.
31. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time: why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 1996;16:1568-1572.
32. Rainwater DL, Kammerer CM. The lipoprotein Lp(a): effects of allelic variation at the LPA locus. J Exp Zool. 1998;282:54-61.
33. Rainwater DL. Stability of apolipoprotein(a) isoform phenotype to postmortem conditions. Clin Chim Acta. In press.
34. Rainwater DL, Kammerer CM, VandeBerg JL, Hixson JE. Characterization of the genetic elements controlling lipoprotein(a) concentrations in Mexican Americans: evidence for at least three controlling elements linked to LPA, the locus encoding apolipoprotein(a). Atherosclerosis. 1997;128:223-233.
35. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.
36. Coresh J, Kwiterovich PO. Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. JAMA. 1996;276:914-915.
37. Tailleux A, Fruchart JC. HDL heterogeneity and atherosclerosis. Crit Rev Clin Lab Sci. 1996;33:163-201.
38. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33:495-543.
39. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
40. Avogaro P, Bon GB, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet. 1979;1:901-903.
41. De Backer G, Rosseneu M, Deslypere JP. Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis. 1982;42: 197-203.
42. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983;309:385-389.
43. Kottke BA, Zinsmeister AR, Holmes DR Jr, Kneller RW, Hallaway BJ, Mao SJT. Apolipoproteins and coronary artery disease. Mayo Clin Proc. 1986;61:313-320.
44. Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem. 1996;42:489-491.
45. Lyu L-C, Shieh M-J, Ordovas JM, Lichtenstein AH, Wilson PWF, Schaefer EJ. Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. Arterioscler Thromb. 1993;13:1429-1440.
46. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.
47. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.
48. Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1994;14:1098-1104.
49. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis. 1984;4:79-83.
50. Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, Després J-P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955-1961.
51. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
52. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270: 2195-2199.
53. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu Q-T, Miller CG, Lawn RM, Scanu AM. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A. 1987; 84:3224-3228.
54. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
55. Harpel PC, Hermann A, Zhang X, Ostfeld I, Borth W. Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost. 1995;74: 382-386.
56. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med. 1996;47:423-442.
57. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis. 1986;62:249-257.
58. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997; 17:2783-2792.
59. Leerink CB, Duif PFCCM, Gimpel JA, Kortlandt W, Bouma BN, Van Rijn JM. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost. 1992;68:185-188.
60. Scanu AM, Pfaffinger D, Lee JC, Hinman J. A single point mutation (Trp72->Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta. 1994;1227:41-45.
61. Klezovitch O, Edelstein C, Scanu AM. Evidence that the fibrinogen binding domain of apo(a) is outside the lysine binding site of kringle rV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. J Clin Invest. 1996;98:185-191.
62. Kang C, Durlach V, Soulat T, Fournier C, Anglés-Cano E. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler Thromb Vasc Biol. 1997;17: 2036-2043.
63. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.
64. Kraft HG, Lingenhel A, Köchl S, Hoppichler F, Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16:713-719.
65. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA. 1997;277:1689-1695.
66. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, Schroll M, Faergeman O. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis. 1997;132:77-84.